DA PAM 40–8

Occupational Health Guidelines for the Evaluation and Control of Occupational Exposure to Nerve Agents GA, GB, GD, and VX

This revision is a health related publications developed to complement existing and future Occupational Safety and Health Administration (OSHA) and safety requirements. It–

o Adds occupational health information about the nerve agents GA, GD, VX (integrated throughout).

o Updates occupational health information about agents GB (integrated throughout).

o Explains how to request a waiver or exception (para 1-4).

o Removes the pregnancy limitations, since teratogenicity studies for agents GB and VX have been negative.

o Updates guidance about optical inserts (para 2-4c), contact lenses (para 2-4d), the selection of raspatory protection equipment (para 2-4e), exposure monitoring (para 2-5), recordkeeping requirements (para 3-1), hazard communication information (para 3-3d), and material safety data sheets (para 3-4).

o Clarifies the policies with regard to qualitative fit testing using isoamyl acetate and irritant fume (para 2-4e and app C).

o Aligns tables 2-1 and 2-2 with the format to be used in future Department of the Army safety regulations.

o Reduces the number of atmospheric monitoring records that must be maintained in the occupational health record by defining criteria for exposure and potential exposure (para 3-1c (2)).

o Redefines the nerve agent exposure categories A, B, C, and D (para 4-2).

o Clarifies the role of the surety officer or safety officer in categorizing exposure potential (para 4-2).

o Clarifies the roles of the installation or activity commander and installation medical authority or designated contract physician in the medical surveillance program (paras 4-4 and 4-5).

o Establishes responsibility for provided cholinesterase (red blood cellcholinesterase (RBC-ChE)) monitoring for Department of Defense (DOD) contractor employees (para 4-8b).

o Provides guidance about cholinesterase (RBC-ChE) monitoring for transient visitors (para B-3).

o Defines the examining physician’s responsibilities regarding abnormal findings in the preplacement and periodic examinations (paras B-4 and B-8 respectively).

o Updates guidance on establishing baseline RBC-ChE (para B-12).

o Updates the diagnosis and treatment guidelines (app D).

o Defines terms such as designated contract physician, agent operating area, and exposed worker.


Download (PDF, 65KB)